GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ignyta Inc (NAS:RXDX) » Definitions » 3-Year RORE %

Ignyta (Ignyta) 3-Year RORE % : 0.00% (As of Sep. 2017)


View and export this data going back to 2014. Start your Free Trial

What is Ignyta 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Ignyta's 3-Year RORE % for the quarter that ended in Sep. 2017 was 0.00%.

The industry rank for Ignyta's 3-Year RORE % or its related term are showing as below:

RXDX's 3-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -6.865
* Ranked among companies with meaningful 3-Year RORE % only.

Ignyta 3-Year RORE % Historical Data

The historical data trend for Ignyta's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ignyta 3-Year RORE % Chart

Ignyta Annual Data
Trend Aug12 Aug13 Dec14 Dec15 Dec16
3-Year RORE %
- - - - -

Ignyta Quarterly Data
Nov12 Feb13 May13 Aug13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ignyta's 3-Year RORE %

For the Biotechnology subindustry, Ignyta's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ignyta's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ignyta's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Ignyta's 3-Year RORE % falls into.



Ignyta 3-Year RORE % Calculation

Ignyta's 3-Year RORE % for the quarter that ended in Sep. 2017 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -2.7--3.2 )/( -9.37-0 )
=0.5/-9.37
=-5.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2017 and 3-year before.


Ignyta  (NAS:RXDX) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Ignyta 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Ignyta's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ignyta (Ignyta) Business Description

Traded in Other Exchanges
N/A
Address
Ignyta is an oncology biotechnology company. Its research is targeting tumor reduction and cancer treatment through both integrated therapeutic and companion diagnostics. The integrated therapeutic segment aims to discover, develop, and commercialize molecularly targeted therapies. The companion diagnostic segment aims to pair the discovered therapies with biomarker-based companion diagnostics to precisely identify, at the molecular level, patients likely to have good results. The company's portfolio includes compounds to treat adult patient populations for solid tumors, pediatric patients with advanced solid tumor malignancies, and patients with superficial and nodular basal cell carcinoma.
Executives
James L Freddo director 3115 MERRYFIELD ROW, SAN DIEGO CA 92121
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Pratik S Multani officer: Chief Medical Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Jonathan E Lim director, 10 percent owner, officer: President, CEO & Director 11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jacob Chacko officer: Chief Financial Officer C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Igor Bilinsky officer: GM, Immuno-Oncology/SVP Sp Ops C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Matthew Onaitis officer: General Counsel and Secretary C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Adrian Senderowicz officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024

Ignyta (Ignyta) Headlines

From GuruFocus

Steven Cohen Dives Deeper Into Health Care

By Graham Griffin Graham Griffin 03-23-2021